NetForum uses cookies to ensure that we give you the best experience on our website. If you continue to use the site, we'll assume that you are happy to receive these cookies on the NetForum website. Read about our cookies.
NetForum Community
Learn. Share. Optimize.
Log in | Sign up now | Submit content | Contact

Attention valued NetForum members:

Due to evolving technology needs and global privacy regulations, we have made the hard decision to suspend the NetForum User Community platform on Friday, November 29, 2019.

After this date, the current NetForum can no longer be reached. Please click here for more information about this decision, what happens next and how to stay in touch with us about the future of the community.

Go to similar content

CT-perfusion technique, with evaluation of quantitative perfusion map, as an early predictor for tumour response to transarterial chemoembolization in patients with HCC lesions

Philips CT Clinical Science Philips Healthcare • USA

PA Bonaffini, D Ippolito, C Talei Franzesi, C Capraro, R Corso, S Sironi, Monza/IT. 

The purpose of this study was to prospectively investigate the role of CT-perfusion (CT-p) technique in evaluation of perfusion changes in HCCs before and after transarterial chemoembolization (TACE) therapy.

Material and Methods
Twenty-seven patients with cirrhotic liver disease and histologically proved HCC were prospectively enrolled in our study. CT-p study was performed on 16 multidetector CT (Brilliance CT 16-slice, Philips, NL), dose exposure was 120 V, 80 mAs. In all cases, bolus injection of 50 ml of nonionic contrast agent (350 mgI/ml) at a flow rate of 6 ml/sec was performed and forty dynamic scans were acquired at a fixed table position. A dedicated perfusion software which generated a quantitative map of arterial and portal perfusion by means of colour scale was employed. The following perfusion parameters were assessed before and after TACE:
  • Hepatic perfusion (HP)
  • Arterial perfusion (AP)
  • Blood volume (BV)
  • Hepatic perfusion index (HPI)

A complete HCC filling by lipiodol was found in 18 cases with following perfusion parameters: HP 32.7±15.1 ml/sec/100 gr; AP 38.4±8.8 ml/min; BV 17.6±9.5 ml/100 mg; HPI 96.2 ±7.5%. Corresponding value calculated in patients without residual tumor were: HP 13.6±6.3; AP 13.1±7; BV 6.8±4.8; HPI 13.6±9.2. A significant difference (p<0.001) was found for all parameters between residual viable tumor tissue (p<0.001) compared to successfully treated lesion, due to the presence of residual arterial vascular structure in viable portion of treated HCC.

On the basis of the small patient population, this feasibility study shows that quantitative analysis of perfusion could provide an in vivo early biomarker for predicting treatment response in patients with HCC lesions.

This content has been made possible by NetForum Community.
Share this on: Share your link in twitter Share your link in facebook Share your link on LinkedIn Print Rate this article: Log in to vote

Jun 12, 2012

Rate this:
Log in to vote

Brilliance 16-slice
abdomen, Body, bolus tracking, contrast, lesion, liver, liver perfusion, Perfusion, tumor

Clinical News
Best Practices
Case Studies
Publications and Abstracts
White Papers
Web seminars and Presentations
Application Tips and FAQ
Try an Application
Business News
Case Studies
White Papers
Web Seminars and Presentations
Utilization Services
Contributing Professionals
Contributing Institutions
Become a Contributor